Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT04858217 Recruiting - Clinical trials for Prosthetic Joint Infection

Periprosthetic Joint Infections: Diagnostic Accuracy and Cost-effectiveness Analysis of Serum and Synovial Markers

DECISION
Start date: February 1, 2022
Phase:
Study type: Observational

Total joint replacement (TJR) is an increasing effective procedure in orthopedics. However, TJR failure due to aseptic or septic loosening remains an important problem, often due to predisposing factors of the patient, which determine the need to perform a revision surgery. In light of the recent conclusions emerged on the still open problems concerning the diagnostic accuracy of serum and synovial fluid markers in the diagnosis of peri-prosthetic joint infection (PJI), the project aims at evaluating the diagnostic accuracy and cost-effectiveness of the combination of serum and/or synovial markers in the diagnosis of PJI. Through a diagnostic clinical study on patients hospitalized for revision surgery the project would provide evidences on the potentiality of the combination of some markers in accelerating the PJI diagnosis for the best selection of surgical strategy, choosing the suitable cutoff thresholds to mitigate the effect of some factors on markers' discriminatory capability.

NCT ID: NCT04856878 Not yet recruiting - Clinical trials for Central Line-associated Bloodstream Infection (CLABSI)

Effect of Vancomycin After Catheter Replacement

VanCat
Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Randomized controlled trial of the effect of a single-dose intravenous Vancomycin after catheter replacement for suspected central line-associated bloodstream infection on resolution of infection in critically ill patients.

NCT ID: NCT04854941 Completed - Clinical trials for Coronavirus Infection

Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection

Start date: December 10, 2020
Phase: N/A
Study type: Interventional

The treatment of the new coronavirus infection (COVID-19) and COVID-19-associated diarrhoea and liver injury remains challenging. Optimizing treatment approaches for COVID-19 remains an issue. It is assumed, that changes in composition of intestinal microbiota is closely related to a change in the regulation of the immune response in the lungs in patients with COVID-19. These gut microbiota changes in combination with antibiotic prescription during the treatment increase the risk of antibiotic-associated diarrhea and C. difficile infection as well as worse clinical outcomes in these patients. Probiotics are useful for restoring the human gut microbiome and increasing anti-inflammatory response also. Despite the variety of uses of probiotics, there is still insufficient data on the clinical efficacy of including probiotics in the treatment of patients with COVID-19 infection.

NCT ID: NCT04851015 Not yet recruiting - Clinical trials for Pneumocystis Pneumonia

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

LOW-TMP
Start date: June 2022
Phase: Phase 3
Study type: Interventional

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

NCT ID: NCT04850677 Completed - Clinical trials for Salmonella Infection Non-Typhoid

Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study

TreNTS
Start date: August 1, 2021
Phase:
Study type: Observational

With this study the researchers aim to provide observational data on the treatment efficacy of currently used antibiotic treatment regimens for NTS BSI in hospital-admitted children. The study is an observational cohort study where the antibiotic treatments used and treatment outcomes in the St. Luc general referral hospital in Kisantu health zone (Province Kongo Central, DR Congo) will be described.

NCT ID: NCT04848883 Recruiting - Infectious Disease Clinical Trials

Infectious Diseases Experts as Part of the Antibiotic Stewardship Team in Primary Care

IDASP
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

A cluster-randomised multicentre blinded clinical trial will be performed in six primary care centres located in the southern metropolitan area of Barcelona (Spain). The objective is to assess whether including experts on infectious diseases (ID) within the antimicrobial stewardship (AMS) team of primary care achieves higher reductions on overall antibiotic consumption and increases the quality of prescription in diagnosed upper respiratory and urinary tract infections. Centres will be randomly assigned to receive a standard-AMS or an advanced-AMS (intervention). Advanced-AMS includes all standard-AMS strategies plus general practitioner chance to discuss clinical cases by telephone to ID expert on working days (8:00 am to 8:00 pm), and by biweekly meetings.

NCT ID: NCT04848610 Completed - COVID-19 Infection Clinical Trials

The Factors That Affect the Infection of COVID-19

Start date: October 18, 2020
Phase:
Study type: Observational

The number of new Coronavirus-2019 (Covid-19) cases is increasing day by day despite the warnings "Stay at home! Wear a mask! Keep social distance!". The aim of this descriptive study is to determine the risk factors that affect the Covid-19 infection in Turkey. The online link of the form created on Google forms was sent to the participants' phones between 18.10.2020 and 18.11.2020.

NCT ID: NCT04848441 Not yet recruiting - Covid19 Clinical Trials

Risk of COVID-19 Infection After Vaccination

Start date: May 1, 2021
Phase:
Study type: Observational

The purpose of this observational nationwide study is to evaluate the effects of three different COVID-19 vaccines for the outcome of different severities of incident COVID infection.

NCT ID: NCT04847921 Terminated - Clinical trials for Substance Use Disorders

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

SUDDEN-OUT
Start date: April 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The Investigators aim to study the outcomes of serious infections due to vancomycin susceptible infections in gram-positive organisms susceptible to vancomycin in people who use drugs (PWUD). The Investigators hypothesize, that a simplified 2-dose dalbavancin regimen, will improve compliance with antimicrobial therapy and that it may facilitate engagement in the treatment of the underlying substance use disorder, and particularly injection drug use - often the true etiology behind these severe infections.

NCT ID: NCT04846803 Recruiting - Clinical trials for Recurrent Urinary Tract Infections

Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment

BIrUTI
Start date: January 9, 2024
Phase: N/A
Study type: Interventional

Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health costs. With this protocol, we want to elucidate alternative treatment methods for especially recurrent urinary tract infection. Bacteria have internal competitiveness (bacterial interference) and it is known that the non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies. We intend to strengthen the clinical evidence that it can be used as patient treatment through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.